# Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

> **NCT04676386** · — · TERMINATED · sponsor: **Addario Lung Cancer Medical Institute** · enrollment: 29 (actual)

## Conditions studied

- NSCLC Stage IV
- NSCLC, Stage IIIC

## Interventions

- **DIAGNOSTIC_TEST:** Primary Immune Response (PIR) test by Biodesix, Inc.

## Key facts

- **NCT ID:** NCT04676386
- **Lead sponsor:** Addario Lung Cancer Medical Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Recruitment futility
- **Last updated:** 2024-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676386, "Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*